Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
Morphine sulfate is an opioid analgesic indicated for management of pain in patients requiring opioid therapy. Available as an oral solution formulation, it acts as a mu-opioid receptor agonist to provide systemic pain relief. The product is a legacy NDA approval from 2008 now approaching loss of exclusivity.
Product is in late-stage lifecycle with moderate competitive pressure (60/100), indicating defensive positioning and focus on margin management rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Working on morphine sulfate offers career opportunity in defensive market management and supply chain optimization for a cornerstone analgesic product. Roles emphasize cost management, compliance, and operational efficiency rather than commercial expansion or innovation.
Worked on MORPHINE SULFATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo